Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blind, placebo controlled, single and multiple dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670 in male and female healthy subjects and patients with myasthenia gravis

Next Previous
X
Search
Trial Profile

A randomised, double-blind, placebo controlled, single and multiple dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NMD670 in male and female healthy subjects and patients with myasthenia gravis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bromophenoxyazole propanoic acid (Primary)
  • Indications Myasthenia gravis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms CHDR1948
  • Sponsors NMD Pharma

    • Most Recent Events

    • 03 Oct 2023 According to a NMD Pharma media release, data from this study will be presented at the 28th International Annual Congress of the World Muscle Society taking place at the Charleston Convention Center in Charleston, South Carolina, US from 3-7 October.
    • 08 Sep 2023 According to a NMD Pharma media release, company will be hosting a satellite symposium and presenting new data from this clinical trial at the conference,The 148th Annual Meeting of the American Neurological Association taking place from 9-12 September, Philadelphia, US.
    • 11 Oct 2022 Topline results published in a NMD Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top